Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study. [PDF]
J Asthma AllergyPurpose Real-world evidence of benralizumab effectiveness on nasal polyps (NP) and asthma outcomes in patients with severe eosinophilic asthma (SEA) and comorbid chronic rhinosinusitis with NP are limited. The objective of this study was to assess NP and
Le TT +12 more
europepmc +2 more sources
Eosinophilic bioactivities in severe asthma [PDF]
World Allergy Organization Journal, 2016 Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through ...
Tara F. Carr +4 more
doaj +5 more sources
Frontiers in Pharmacology, 2022 Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a
Luisa Ricciardi +5 more
doaj +2 more sources
MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA [PDF]
Chest, 2020 Qaisar Shahzad, Mohd Moonis Zaheer
openalex +3 more sources
Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial [PDF]
ERJ Open ResearchBackground Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma.
Lina Brinkmann +4 more
doaj +2 more sources
Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP [PDF]
Journal of Asthma and AllergyJuan Luis Garcia-Rivero,1,2 Beatriz Abascal-Bolado,1 Nieves Aranda Sobrino,2 Cristina Ghadban Garrido2 1Respiratory Department, Marqués de Valdecilla University Hospital, Santander, Spain; 2Valdecilla Research Institute (IDIVAL), Santander ...
Garcia-Rivero JL +3 more
doaj +1 more source
Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series [PDF]
Drugs in ContextBackground: Patients with severe asthma are often dependent on oral corticosteroids (OCS) and have frequent exacerbations. This article aims to report very long-term data of patients with severe eosinophilic asthma assessing asthma control, lung function,
Carlo Lombardi +2 more
doaj +2 more sources
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
Biomedicines, 2022 Severe asthma is characterized by different endotypes driven by complex pathologic mechanisms. In most patients with both allergic and non-allergic asthma, predominant eosinophilic airway inflammation is present.
Alessandro Vatrella +5 more
doaj +1 more source
Biomarkers for severe eosinophilic asthma [PDF]
Journal of Allergy and Clinical Immunology, 2017 The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic
Yancey, S +6 more
openaire +3 more sources
Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
Respirology Case Reports, 2021 Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5).
Venkata Nagarjuna Maturu +7 more
doaj +1 more source